Olema Pharmaceuticals (OLMA) Capital Expenditures (2020 - 2024)
Olema Pharmaceuticals (OLMA) posted quarterly Capital Expenditures of $6000.0 for Q2 2024, down 96.08% quarter-over-quarter from $153000.0 in Q1 2024.
Olema Pharmaceuticals (OLMA) Capital Expenditures (2020 - 2024) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Capital Expenditures for 4 consecutive years, with $6000.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Capital Expenditures changed N/A year-over-year to $6000.0; the TTM figure through Sep 2025 stood at $6000.0 (down 98.19% YoY), while the FY2024 annual figure was $159000.0, changed N/A from the prior year.
- Capital Expenditures eased to $6000.0 in Q2 2024 per OLMA's latest filing, from $153000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $813000.0 in Q3 2021 and bottomed at -$10000.0 in Q3 2020.
- Historically, Capital Expenditures has averaged $153785.7 across 4 years, with a median of $34500.0 in 2021.
- Annual changes were most pronounced in 2021 — Capital Expenditures jumped 8230.0% — and 2022, when it slumped 82.9%.
- Olema Pharmaceuticals' Capital Expenditures stood at $51000.0 in 2020, then soared by 1270.59% to $699000.0 in 2021, then plunged by 75.25% to $173000.0 in 2022, then sank by 96.53% to $6000.0 in 2024.
- Business Quant data shows OLMA's Capital Expenditures at $6000.0 in Q2 2024, $153000.0 in Q1 2024, and $173000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2022 | 173,000.00 |
| Dec 31, 2022 | 173,000.00 |
| Sep 30, 2022 | 139,000.00 |
| Sep 30, 2022 | 139,000.00 |
| Jun 30, 2022 | 21,000.00 |
| Jun 30, 2022 | 21,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Dec 31, 2021 | 699,000.00 |
| Dec 31, 2021 | 699,000.00 |
| Sep 30, 2021 | 813,000.00 |
| Sep 30, 2021 | 813,000.00 |
| Jun 30, 2021 | 24,000.00 |
| Jun 30, 2021 | 24,000.00 |
| Mar 31, 2021 | 39,000.00 |
| Mar 31, 2021 | 39,000.00 |